
    
      This is a randomized, double-blind, parallel clinical trial of lipoic acid for inflammatory
      factors, insulin resistance, glycemic control and anthropometric indices in patients with
      metabolic syndrome. patients are randomly shared into two groups and received 600 mg
      supplemental and placebo for 12 weeks, Then the body mass index, waist circumference,
      systolic and diastolic blood pressure, FBS (fasting blood sugar), lipid profile ,HbA1C, serum
      insulin concentration, TAC, CRP and TNF-a , Insulin resistance are measured ;All these steps
      will be done at the start and end of the study.
    
  